The chairman of the National Council, Wolfgang Sobotka, is said to have intervened for institutes near the ÖVP. Financial assessments should now relieve him.
Thomas Schmid, ex-financial general and key witness in the corruption case involving Sebastian Kurz’ turquoise ÖVP, wants to be a key witness and has extracted 455 pages extensively. The ÖVP wants to portray the former tug-of-war as a storyteller. “Schmid is lying. This can be proven once again,” says Andreas Hanger. The faction leader in the U-Commission points to evidence. In the case of Wolfgang Sobotka, chairman of the National Council and chairman of the Committee. According to Schmid, he would have intervened in tax cases at the Alois Mock Institute and the Erwin Proell Foundation.
An e-mail dated October 29 from an official to a section chief tells a different story. The Proell Foundation has therefore been certified as a non-profit organization twice. Support of a music student of 9909 euros could not be recognized for tax purposes. It was a “minor problem” and no action was taken.
The Mock Institute is more explosive. Above all, the SPÖ regularly targets Sobotka, thanks in part to donations from Novomatic. Schmid claimed to the WKStA that a tax audit on behalf of Sobotka had been prevented. The official responsible states: “In the entire period from 2014 to 2019, no tax audit took place and was never planned.”
For Hanger, Sobotka, who vehemently denies the allegations, has been “completely acquitted”. The opposition and the Greens, on the other hand, want to get to the bottom of the matter. Reports such as “ZackZack” about a “task force in the Treasury Department” to search for exculpatory material for the ÖVP are against. It’s invented. “We answer what we are legally allowed to answer. Research is only done when necessary.”
Source: Krone

I’m an experienced news author and editor based in New York City. I specialize in covering healthcare news stories for Today Times Live, helping to keep readers informed on the latest developments related to the industry. I have a deep understanding of medical topics, including emerging treatments and drugs, the changing laws that regulate healthcare providers, and other matters that affect public health.